Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Overview of Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company dedicated to advancing the treatment of central nervous system (CNS) disorders through precision medicine. By translating genetic insights into innovative therapies, Praxis addresses conditions characterized by neuronal excitation-inhibition imbalances. The company’s diversified portfolio spans multiple clinical-stage candidates, focusing on rare and prevalent neurological disorders, including epilepsy, essential tremor, and developmental and epileptic encephalopathies (DEEs).
Core Business Areas
Praxis operates at the intersection of neuroscience and precision medicine, leveraging two proprietary platforms: Cerebrum™, which focuses on small molecule therapeutics, and Solidus™, an antisense oligonucleotide (ASO) platform. These platforms enable Praxis to target shared biological pathways and circuits implicated in CNS disorders, offering a multimodal approach to drug discovery and development.
Pipeline and Product Candidates
- Ulixacaltamide: A highly selective T-type calcium channel inhibitor designed to treat essential tremor by modulating abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical circuit.
- Vormatrigine (PRAX-628): A next-generation sodium channel modulator targeting focal onset seizures and generalized epilepsy, demonstrating superior selectivity and efficacy in preclinical and early clinical studies.
- Relutrigine (PRAX-562): A first-in-class sodium channel modulator for DEEs, including SCN2A- and SCN8A-related epilepsies, with potential applications in broader developmental epilepsies.
- Elsunersen (PRAX-222): An ASO targeting SCN2A gain-of-function mutations in early-onset DEE, aiming to be the first disease-modifying therapy for this condition.
Strategic Collaborations
Praxis has established partnerships with leading organizations, including Ionis Pharmaceuticals and RogCon, to enhance its capabilities in genetic epilepsy research. These collaborations strengthen the company’s ability to address rare pediatric diseases and expand its reach in the CNS therapeutic landscape.
Market Position and Differentiation
Operating within the competitive CNS therapeutics market, Praxis differentiates itself through its precision medicine approach, focusing on unmet needs in both rare and common neurological disorders. By prioritizing conditions with limited treatment options, Praxis positions itself as a key innovator in the biopharmaceutical industry.
Challenges and Opportunities
While Praxis faces challenges such as regulatory complexities and competition from established pharmaceutical companies, its focus on precision sodium channel modulators and disease-modifying therapies provides significant growth opportunities. The company’s ability to advance its clinical programs and secure regulatory approvals will be critical to its long-term success.
Conclusion
Praxis Precision Medicines, Inc. exemplifies innovation in CNS therapeutics, leveraging genetic insights and advanced platforms to develop targeted therapies. With a robust pipeline and strategic collaborations, Praxis is well-positioned to address critical unmet needs in neurological disorders, offering hope to patients and caregivers worldwide.
Praxis Precision Medicines (NASDAQ: PRAX) has scheduled an end-of-phase 2 meeting with the FDA for ulixacaltamide, aimed at treating Essential Tremor (ET), in June 2023. The company will also present key findings from its Essential1 trial at various medical conferences, including the 75th Annual AAN on April 23, 2023, and the World Congress on Parkinson’s Disease on May 15, 2023. Ulixacaltamide is a selective T-type calcium channel blocker designed to mitigate tremor activity, a common neurological disorder affecting roughly seven million people in the U.S. The current pharmacotherapy options are limited, underscoring the need for effective treatments, which may position ulixacaltamide favorably in the market.
Praxis Precision Medicines (NASDAQ: PRAX) has announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 12:45 p.m. ET. The presentation will be accessible via a live webcast on the company's website, with a replay available for 90 days post-event.
Praxis focuses on developing therapies for central nervous system (CNS) disorders that stem from neuronal excitation-inhibition imbalances. The company utilizes its proprietary platforms, Cerebrum™ and Solidus™, to leverage genetic insights for creating therapies for rare and prevalent neurological conditions. With a diverse portfolio, Praxis has multiple clinical-stage product candidates targeting movement disorders and epilepsy.
BOSTON, March 3, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines (NASDAQ: PRAX), focused on CNS disorders, will participate in key investor conferences. They will take part in the 43rd Annual TD Cowen Health Care Conference on March 6, 2023, featuring a panel on orphan epilepsies at 12:50 p.m. ET. Additionally, Praxis will join the Needham Neuroscience Forum for a fireside chat on March 15, 2023, at 2:00 p.m. ET. Both events will be accessible via live webcast on their website, with replays available for 30 days post-event. Praxis is advancing therapies for neurological disorders using its proprietary platforms.
Praxis Precision Medicines (NASDAQ: PRAX) announced topline results from the Phase 2b Essential1 study of ulixacaltamide for treating essential tremor. The primary endpoint of improvement in modified Activities of Daily Living (mADL) did not reach statistical significance (p=0.126), but a secondary endpoint, the TETRAS-ADL, showed nominal significance (p=0.026). The drug was well tolerated, with no new safety findings reported. Praxis plans to engage with the FDA for an end-of-Phase 2 meeting and initiate a Phase 3 study in 2H23, as the unmet need for effective therapies for essential tremor persists.
Praxis Precision Medicines (NASDAQ: PRAX) provided a corporate update and financial results for Q4 and full year 2022, highlighting a transformative 2023 ahead with topline results from the ulixacaltamide Essential1 study expected in 1Q23. The company reported cash and investments of $100.5 million as of December 31, 2022, which funds operations into 1Q24. R&D expenses increased to $155 million in 2022, with net losses of $214 million.
Key milestones for 2023 include results from their clinical programs, including PRAX-562 and PRAX-628. A strategic collaboration with UCB could yield up to $100 million in milestone payments for the KCNT1 program.
Praxis Precision Medicines (NASDAQ: PRAX) has announced a strategic collaboration with UCB focused on developing small molecule therapeutics for KCNT1 related epilepsies, which currently have no approved treatments. The partnership will allow Praxis to leverage UCB's experience in epilepsy drug development. Praxis will receive an upfront payment and could earn up to approximately $100 million in milestone payments, along with royalties from any resulting products. This collaboration underscores Praxis' commitment to advancing treatments for genetic epilepsy disorders.
BOSTON, Nov. 28, 2022 – Praxis Precision Medicines (NASDAQ: PRAX) announced presentations regarding its epilepsy programs at the American Epilepsy Society (AES) 2022 Annual Meeting from December 2-6, 2022. The company will discuss its programs PRAX-222, PRAX-562, and PRAX-628, including first-in-patient studies and findings on developmental and epileptic encephalopathies (DEE). Key studies highlight PRAX-562's anticonvulsant activity across multiple models and insights into SCN2A and SCN8A-related DEE, potentially influencing future treatment endpoints and therapies.
Praxis Precision Medicines (PRAX) has received FDA authorization to proceed with the PRAX-562 Phase 2 EMBOLD study targeting pediatric patients with developmental and epileptic encephalopathies (DEEs). The study will commence in Q1 2023, focusing on SCN2A-DEE and SCN8A-DEE cohorts. Topline results are expected in late 2023. PRAX-562 aims to offer a precision treatment option, using a sodium channel inhibitor that has shown promising results in preclinical models. The company has received multiple orphan drug designations, underscoring the potential impact of this treatment.
Praxis Precision Medicines (NASDAQ: PRAX) reported a Q3 2022 net loss of $43.9 million, with cash and investments at $123.7 million, expected to fund operations until Q1 2024. Upcoming topline results for the PRAX-944 Essential1 study on essential tremor are anticipated in Q1 2023, while the PRAX-222 EMBRAVE study for SCN2A-DEE is set to initiate in Q4 2022. The company has adjusted its Parkinson's disease study design and plans to meet with the FDA regarding Phase 3 development following Essential1 results.
Praxis Precision Medicines (NASDAQ: PRAX) announced participation in two investor conferences. Management will join the Guggenheim’s 4th Annual Immunology and Neurology Conference on November 14, 2022, at 10:45 a.m. ET, and the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 1:00 p.m. ET. Both events will feature live webcasts available on the company’s website, with replays accessible for 30 days post-event. Praxis is focused on developing therapies for CNS disorders using genetic insights, with a portfolio that includes four clinical-stage product candidates.
FAQ
What is the current stock price of Praxis Precision Medicines (PRAX)?
What is the market cap of Praxis Precision Medicines (PRAX)?
What does Praxis Precision Medicines specialize in?
What are Praxis' key product candidates?
How does Praxis differentiate itself in the biopharmaceutical industry?
What therapeutic areas does Praxis target?
What is the significance of Praxis' proprietary platforms?
What challenges does Praxis face in its market?
Who are Praxis' key collaborators?
What is unique about Praxis' approach to epilepsy treatment?
What is the focus of the EMBOLD study?
What is Elsunersen's role in Praxis' pipeline?
